Completed PHASE4 INTERVENTIONAL 3-arm NCT01437995

Long-acting Beta Agonist Step Down Study (LASST)

Sponsor: American Lung Association

Conditions Asthma

Interventions Fluticasone Diskus Fluticasone/Salmeterol Diskus

Updated 9 times since 2017 Last updated: Mar 14, 2017 Started: Mar 31, 2012 Primary completion: Sep 30, 2015 Completion: Oct 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01437995, this PHASE4 trial focuses on Asthma and remains completed. Sponsored by American Lung Association, it has been updated 9 times since 2012, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2021 — Dec 2021 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jun 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — Jun 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Mar 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

American Lung Association
GlaxoSmithKline
Johns Hopkins University

Data source: Johns Hopkins University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Charlottesville, United States , Chicago, United States , Colchester, United States , Columbus, United States , Denver, United States , Durham, United States , Houston, United States , Indianapolis, United States , Jacksonville, United States , Kansas City, United States and 8 more locations